Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 3 EP applications Lucy Clare Padget has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after January 30, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11746295

N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS

IPC classification:
A61K 31/445, A61P 35/00, A61P 35/02, C07D 211/22
Applicant:
AstraZeneca AB
Agent:
Multiple attorneys, AstraZeneca AB
Agent:
Jan Peter Storm, AstraZeneca PLC
Agent:
Lucy Clare Padget, AstraZeneca UK Limited
Status:
The patent has been granted
EP14710620

QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR

IPC classification:
A61K 31/495, A61K 31/505, C07D 403/12
Applicant:
AstraZeneca AB
Agent:
Multiple attorneys, Kilburn & Strode LLP
Agent:
Lucy Clare Padget, AstraZeneca UK Limited
Status:
The patent has been granted
EP11783835

NEW PROCESS FOR THE PREPARATION OF ARYL SUBSTITUTED OLEFINIC AMINES

IPC classification:
C07C 29/40, C07C 211/21, C07C 231/14, C07D 213/65
Applicant:
AstraZeneca AB
Agent:
Charlotte Waveney Crowhurst, Potter Clarkson LLP
Agent:
Lucy Clare Padget, AstraZeneca AB
Status:
APPLICATION DEEMED TO BE WITHDRAWN

Please Sign in to use this feature